NCT02305732 - A Prospective, Open Label, Treatment Use Study of Patient Safety Following Transfusion of INTERCEPT Platelet Components | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions

Chikungunya VirusDengue Virus

Interventions

BIOLOGICAL

INTERCEPT Platelets

INTERCEPT platelet components (PC). Leukocyte reduced apheresis platelet components collected in Platelet Additive Solution (PAS) or 100% plasma without gamma irradiation, bacterial detection, and Cytomegalovirus (CMV) serology testing.

Trial Locations (8)

00705

Hospital General Menonita de Aibonito, Aibonito

00725

Hospital General Menonita de Caguas, Caguas

Unknown

Hospital General Menonita de Cayey, Cayey

00674

Center Hospital Manati, Manatí

00733

Hospital San Lucas Ponce, Ponce

00683

Hospital La Concepcion San German, San Germán

Centro Cardiovascular de Puerto Rico and the Caribbean, San Juan

00921

Veteran Administration, San Juan